Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2026)

Catalyst Pharmaceuticals has reported Gross Margin for 8 years, with the latest figure at 90.31% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 298.0% year-over-year to 90.31%; the trailing twelve-month figure through Mar 2026 stood at 85.96% (down 16.0% YoY), and the FY2025 full-year result was 85.19%, down 81.0% from the prior year.
• Gross Margin for Q1 2026 stood at 90.31%, up from 82.91% in the prior quarter.
• The five-year high for Gross Margin was 90.31% in Q1 2026, with the low at 81.57% in Q4 2022.
• Historically, Gross Margin has averaged 85.91% across 5 years, with a median of 85.94% in 2025.
• Annual changes were most pronounced in 2022 — Gross Margin slumped 211 bps — and 2023, when it jumped 413 bps.
• Catalyst Pharmaceuticals' Gross Margin stood at 81.57% in 2022, then advanced by 5 bps to 85.7% in 2023, then retreated by 1 bps to 84.74% in 2024, then declined by 2 bps to 82.91% in 2025, then gained by 9 bps to 90.31% in 2026.
• The last three Gross Margin figures came in at 90.31% (Q1 2026), 82.91% (Q4 2025), and 84.73% (Q3 2025), per Business Quant data.